BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Total Revenue Growth Rate (Future 3Y To 5Y Est) : 12.00 (As of May. 03, 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 12.00.

Competitive Comparison of BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

BioCryst Pharmaceuticals (NAS:BCRX) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

BioCryst Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

BCRX:Mexico BO1:Germany BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

http://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Executives

Machelle Sanders	director	C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse	director, officer: CEO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer	officer: Vice President and CCO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones	officer: Exec Director, Finance - PAO	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes	officer: VP, General Counsel & Corp Sec	1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle	officer: Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu	officer: VP Drug Discovery	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie	director	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan	officer: SR VP - CMO	2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee	director	4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson	director	C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703